Endocrine Abstracts

Background and aims: The rs5219 variant in the KCNJ11 have been consistently associated with type 2 diabetes (T2D) and therapeutic response to sulfonylureas in type 2 diabetic patients. However, the impact of KCNJ11 genetic polymorphism on the antidiabetic efficacy of vildagliptin has not yet been evaluated. This study was aimed to investigate the association of KCNJ11 rs5219 with vildagliptin glucose lowering ability by monitoring continuous blood glucose profile.<p class...